Pharmacodynamic Effects of Steady-State Fingolimod on Antibody Response in Healthy Volunteers: A 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Multiple-Dose Study-Reference-Cited by-同舟云学术

Pharmacodynamic Effects of Steady-State Fingolimod on Antibody Response in Healthy Volunteers: A 4-Week, Randomized, Placebo-Controlled, Parallel-Group, Multiple-Dose Study

Published:2012-12 Issue:12 Volume:52 Page:1879-1890
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Boulton Craig,Meiser Karin,David Olivier J.,Schmouder Robert

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference23 articles.

1. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis;Chun;Clin Neuropharmacol,2010

2. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system;Brinkmann;Br J Pharmacol,2009

3. U.S. Food and Drug Administration FDA approves first oral drug to reduce MS relapses http:www.fda.govNewsEventsNewsroomPressAnnouncementsucm226755

4. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis;Cohen;N Engl J Med,2010

5. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis;Kappos;N Engl J Med,2010

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: A single-center prospective study;Vaccine;2024-09

2. Evaluation of single-strain Prevotella histicola on KLH-driven immune responses in healthy volunteers: A randomized controlled trial with EDP1815;Medicine in Microecology;2024-03

3. Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination;Multiple Sclerosis Journal;2023-09-30

4. Latin American consensus recommendations on the risk of infections in people with multiple sclerosis treated with disease modifying drugs;Multiple Sclerosis and Related Disorders;2023-09

5. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines;Frontiers in Immunology;2023-07-20